Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

  title={Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring},
  author={Ludwig Kappos and David W. Bates and Gilles Edan and Mefkure Eraksoy and Antonio Garc{\'i}a‐Merino and Nikolaos Grigoriadis and H. P. Hartung and Eva Kubala Havrdov{\'a} and Jan Hillert and Reinhard Hohlfeld and Marcelo Kremenchutzky and Olivier Lyon‐Caen and Ariel Miller and Carlo Pozzilli and Mads Henrik Ravnborg and Takahiko Saida and Christian J. M. Sindic and Karl Vass and David B. Clifford and Stephen Hauser and Eugene O. Major and P. W. O'Connor and Howard L. Weiner and Michel Clanet and Ralf Gold and Hans H. Hirsch and Ernst Wilhelm Rad{\"u} and Per Soelberg S{\o}rensen and John O King},
  journal={The Lancet Neurology},

Figures from this paper

Treating multiple sclerosis with natalizumab

An overview of the most relevant results from the Phase I–IV studies on natalizumab is provided and the challenges addressed to minimize and manage its adverse events in clinical practice are highlighted.

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society

The MS-SIN Study Group recommendations on the use of NA in MS are summarized, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy

A case of MS is reported in which unusual symptoms in the context of 5 years of natalizumab treatment and seroconversion to JCV antibody positivity led to the initial suspicion of PML and a final diagnosis of Creutzfeldt-Jakob disease (CJD).

Natalizumab therapy for highly active pediatric multiple sclerosis.

The data indicate that natalizumab may be safe and effective against MS in pediatric patients with breakthrough disease.

Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated

Initial observations in 10 multiple sclerosis patients who were stringently monitored up to 6 months after discontinuation of the infusions suggest that in patients who was switched to natalizumab because of disease activity despite first‐line treatment, a natalIZumab drug holiday without reinstatement of alternate disease‐modifying therapy is poorly tolerated.

Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

Recommendations have been developed to guide neurologists in the Middle East and North Africa on patient selection for natalizumab treatment and monitoring and the risk-benefit ratio should be reassessed and discussed with patients.

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

There is currently no convincing evidence that natalizumab-associated PML is restricted to combination therapy with other disease-modifying or immunosuppressive agents.



Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

The patient was hospitalized 2 months after the onset of neurologic and psychiatric symptoms and was treated with plasma exchange and immunoadsorption to eliminate natalizumab, and became critically ill with an apparent episode of immune reconstitution inflammatory syndrome.

Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study

The remarkable efficacy of natalizumab in a group of patients with higher disease activity than that of pivotal studies is confirmed, with a significant reduction compared to the previous year.

Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome

Despite that the baseline characteristics suggested a more severe course of disease in the sample than that of the AFFIRM trial, data on effectiveness of natalizumab were comparable and the presence of antibodies anti-Natalizuab was strongly related to the occurrence of relapses even in the post-marketing experience.

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

The results demonstrate good general tolerability and sustained efficacy of natalizumab for patients with severe MS, though the risk of PML remains a concern.

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing‐remitting multiple sclerosis

The primary objective was to analyse the efficacy of natalizumab on disability status and ambulation after switching patients with RRMS from other disease‐modifying treatments (DMTs).


A patient who developed dramatic clinical and radiologic worsening as a consequence of natalizumab withdrawal after prolonged therapy is reported, which was reminiscent of an immune reconstitution inflammatory syndrome (IRIS).

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Analysis of frozen serum samples showed that JC virus DNA had appeared in the serum three months after the initiation of open-label natalizumab monotherapy and two months before the appearance of symptomatic PML, suggesting that anti-alpha4-integrin therapy can result in JC virus-induced PML.

Natalizumab: Immune effects and implications for therapy

Two articles in this issue of Annals provide the first detailed look at immunological effects of natalizumab treatment in patients with MS, and demonstrate that treatment dramatically reduces the number of cerebrospinal fluid mononuclear cells.